Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Table 1 Tumor size changes in melanoma patients (Ipilimumab-Naive melanoma (KEYNOTE-006))

	Number of Line of Therapy
	1L				2L
	n	Median	Mean	Standard Deviation	n	Median	Mean	Standard Deviation
Pembrolizumab arm
% of Early Tumor Sizes Changes (~Week 12)	282	−24.2	−19.7	42.5	152	−9.1	−9.0	47.2
Best % of Tumor Size Changes	282	−53.0	−40.8	52.4	152	−36.3	−29.1	57.8
Ipilimumab arm
% of Early Tumor Size Changes (~ Week 12)	124	7.8	6.6	46.0	61	−1.6	5.3	62.1
Best % of Tumor Size Changes	124	−6.5	−7.0	56.2	61	−9.7	−6.8	70.2